Undervalued Stocks Right Now: An In-Depth Analysis for Serious Investors
Undervalued stocks right now are not distributed randomly across the market. They cluster in specific sectors, specific geographies, and specific business situations where the market is applying a discount that the underlying economics do not justify. As of Q3 2026, the clearest concentrations are in industrials facing cyclical earnings pressure, healthcare names with litigation overhangs that the market is pricing too harshly, and select non-US financials trading at P/B ratios below cost-of-equity justifications. This analysis maps where genuine undervaluation sits today, using Graham Number, Piotroski F-Score, and DCF intrinsic value as the primary lenses.
Key Takeaways
- Undervalued stocks right now concentrate in industrials, healthcare, and non-US financials where sector dynamics have pushed prices below intrinsic value.
- The Graham Number identifies the mathematical floor for undervaluation on asset-heavy businesses. For franchise businesses, the more relevant tool is normalized earnings yield vs. the risk-free rate.
- The Piotroski F-Score is the most reliable filter for separating genuinely cheap businesses from businesses that are cheap because they are deteriorating.
- JNJ at P/E 15.2 and 3.1% yield, BRK.B at P/B 1.5, and KO at 3.0% yield with 60+ years of dividend growth represent the blue-chip tier of current undervaluation.
- EPS growth rate and beta both inform position sizing once you have identified an undervalued stock.
- The stock market's intraday noise is irrelevant to intrinsic value analysis. The work happens before the open, not during it.
Where Undervalued Stocks Concentrate in 2026
The market does not allocate undervaluation democratically. Understanding where and why it concentrates saves screening time and improves hit rates.
Industrials at cyclical trough. Manufacturing and capital goods companies see earnings compress at the late stage of the economic cycle when order books thin and margin pressure arrives. The market extrapolates the trough as permanent, creating P/E multiples that look expensive on depressed current earnings but cheap on normalized earnings. The Piotroski F-Score is the best filter here because it distinguishes cyclically weak companies from structurally broken ones.
Healthcare with specific litigation risk. JNJ is the prime example. Its trailing P/E of 15.2 versus its own 10-year average of 16.8 reflects a discount applied because of legacy product litigation. The market prices the risk more harshly than a fair expected liability calculation supports. The dividend yield of 3.1%, backed by 60+ consecutive years of dividend growth, reflects a business generating consistent cash that the litigation has not impaired.
Non-US financials. European and Asian banks routinely trade at P/B below 1.0. Most are cheap because they earn less than their cost of equity. A subset earns above cost of equity and trades at sub-1 P/B because of investor home bias and lower analyst coverage. Running the Piotroski F-Score on this subset identifies which sub-1 P/B banks have improving financial health.
Dividend compounders in slow-growth categories. KO at 3.0% yield and 24.1x P/E, and JNJ at 3.1% yield and 15.2x P/E represent companies the market prices for their defensive characteristics rather than their compounding trajectory. Over 20-year holding periods, the reinvested dividend yield dramatically changes the return profile.
The Graham Number as a Screening Anchor
The Graham Number is not a price target. It is a conservative floor estimate that works best for asset-heavy businesses with predictable earnings. The formula: square root of (22.5 x EPS x book value per share).
| Company | EPS | Book Value/Share | Graham Number | Current Price | Notes |
|---|---|---|---|---|---|
| JNJ | $9.80 | $29.40 | $80.50 | $148 | Franchise premium justified by ROIC 17.8% |
| KO | $2.53 | $5.10 | $17.00 | $62 | Franchise premium reflects 42% ROE on low tangible assets |
| BRK.B | $18.40 | $228.60 | $290 | $342 | 18% premium to Graham Number, low for Berkshire historically |
| AAPL | $6.15 | $3.80 | $9.25 | $230 | Graham Number irrelevant; nearly zero tangible book |
| MSFT | $12.80 | $31.20 | $94.90 | $415 | 337% premium; ROIC 35.2% explains the franchise value |
The table confirms what Graham himself acknowledged later in his career: the number does not work for capital-light businesses with strong brands or high ROIC. For those businesses, the correct anchor is normalized earnings yield compared to the risk-free rate. At a 10-year Treasury yield near 4.3% as of late 2026, a stock needs an earnings yield above 5 to 5.5% (P/E below 18 to 20) to offer a meaningful premium for equity risk.
JNJ at P/E 15.2 produces an earnings yield of 6.6%, a 230 basis point premium to the risk-free rate. That premium is meaningful. KO at P/E 24.1 produces 4.1%, about flat to the risk-free rate; the case for KO rests on the 60+ year dividend growth trajectory and inflation-resistant pricing power rather than a raw earnings yield argument.
Piotroski F-Score: Separating Genuine Cheap From Value Traps
The most important filter for undervalued stocks right now is not a valuation metric. It is the Piotroski F-Score, which tests whether the business is financially healthy and improving.
The nine-point scorecard tests profitability (4 criteria), solvency and liquidity (3 criteria), and operational efficiency (2 criteria). Any stock with a score below 4 is deteriorating along multiple dimensions simultaneously. Below is how our benchmark names score:
| Company | Profitability Score | Use Score | Efficiency Score | Total F-Score |
|---|---|---|---|---|
| AAPL | 4/4 | 2/3 | 1/2 | 7/9 |
| MSFT | 4/4 | 3/3 | 1/2 | 8/9 |
| JNJ | 3/4 | 3/3 | 1/2 | 7/9 |
| KO | 3/4 | 2/3 | 2/2 | 7/9 |
| BRK.B | 3/4 | 2/3 | 1/2 | 6/9 |
MSFT's 8/9 is the strongest signal in this set. JNJ and KO at 7/9 are clean. BRK.B at 6/9 reflects the distorting effect of insurance float accounting on accrual and current-ratio measures, not genuine financial deterioration.
For undervalued stocks right now in the industrial and financial sectors, any candidate with a Piotroski score below 5 should be removed from the shortlist unless you have a specific thesis for why the accounting weakness is temporary and calculable.
EPS Growth and Beta: How They Inform Position Sizing
Once you have identified an undervalued stock, two metrics determine how much to own: EPS growth rate and beta.
EPS growth rate. A company with 4% EPS growth (KO) and a 3% dividend yield provides a 7% total return expectation at fair value. A company with 9% EPS growth (AAPL) and 0.5% yield provides 9.5%. If both are undervalued by 20%, the first stock targets 7% total return as it reprices; the second targets 9.5%. The growth rate tells you what you collect after the discount closes.
Beta. Beta measures how much a stock's price moves relative to the index. AAPL at beta near 1.3 and KO at beta near 0.55 will produce very different portfolio volatility profiles even if both are equally undervalued. A portfolio optimizing for sleep-at-night characteristics tilts toward low-beta undervalued stocks. A portfolio optimizing for maximum long-run return at the cost of volatility tilts toward higher-beta candidates with wider margins of safety.
| Company | 5-Year EPS Growth | Beta | Dividend Yield | Total Return Potential at Fair Value |
|---|---|---|---|---|
| AAPL | 9.1% | 1.3 | 0.5% | 9.6% |
| MSFT | 12.0% | 0.9 | 0.8% | 12.8% |
| JNJ | 5.1% | 0.6 | 3.1% | 8.2% |
| KO | 4.2% | 0.55 | 3.0% | 7.2% |
| BRK.B | 6.8% | 0.9 | 0.0% | 6.8% |
The DCF Case for Undervalued Stocks Right Now
DCF analysis converts future earnings into a present value. For undervalued stocks right now, the question is whether the conservative DCF estimate sits materially above the current price.
Running DCF on JNJ with $9.80 current EPS, 5% five-year growth, 3% terminal growth, and 10% discount rate:
- Year 1-5 cash flows: $9.80 growing at 5% = $49.80 cumulative undiscounted
- Terminal value at year 5: $12.52 EPS / (0.10 - 0.03) = $178.86 terminal year value
- Present value of terminal: $111.15 (discounted 5 years at 10%)
- Present value of near-term CFs: $41.30
- Total DCF estimate: $152.45
With JNJ trading near $148, the DCF midpoint suggests the stock is near fair value on conservative assumptions, not deeply undervalued. The opportunity in JNJ is asymmetric: if the litigation overhang resolves favorably, the discount rate compresses and the multiple expands. If it resolves adversely, the $148 price has already discounted much of the damage.
Run your own DCF numbers using the ValueMarkers DCF calculator, which runs four models simultaneously and shows you the sensitivity to growth and discount rate assumptions.
How to Screen for Undervalued Stocks Right Now
The screener applies the full multi-factor framework across 73 global exchanges. The combination that produces the most reliable shortlist of undervalued stocks right now:
- Piotroski F-Score of 7 or higher (eliminates value traps)
- P/E below sector 5-year median (identifies relative discount)
- ROIC above 10% (confirms business quality)
- FCF yield above 4% (confirms cash generation)
- Debt-to-equity below 1.5 (limits financial risk)
- VMCI Value score above 7 (composite confirmation)
Running all six simultaneously narrows the universe to candidates that have cleared quantitative undervaluation checks and quality checks simultaneously. The remaining shortlist requires reading the business, understanding the competitive position, and running a DCF to confirm the margin of safety.
When Is NOW the Right Time to Act on Undervalued Stocks
The right time to buy an undervalued stock is when the margin of safety is adequate and you understand why the discount exists. Not when the market is falling. Not when a macro theme justifies the sector. When the math works and the thesis is clear.
Three conditions accelerate the "right now" case for stocks currently on the shortlist:
The gap between price and DCF midpoint is 25%+. This is a wide enough margin to absorb forecasting errors and still generate meaningful above-market returns.
The Piotroski score has been stable or improving for two years. This confirms the discount is not accompanied by fundamental deterioration.
You can articulate the catalyst. A buyback program, an earnings recovery, a settlement on the litigation overhang, or a sector rerating that closes the gap. Permanent undervaluation is not a thesis; it is a holding pattern.
Further reading: SEC EDGAR · Investopedia
Why stocks trading below book value Matters
This section anchors the discussion on stocks trading below book value. The detailed treatment, formula, and worked examples appear in the body of this article above. The points below summarize the most important takeaways for value investors who want to apply stocks trading below book value in real portfolio decisions. ValueMarkers exposes the underlying data on every covered ticker via the screener and stock profile pages, so the concepts in this article translate directly into actionable filters.
Key inputs for stocks trading below book value
See the main discussion of stocks trading below book value in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using stocks trading below book value alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Sector benchmarks for stocks trading below book value
See the main discussion of stocks trading below book value in the sections above for the full treatment, including the inputs, the calculation methodology, the typical sector benchmarks, and the most common pitfalls to avoid. The ValueMarkers screener lets value investors filter the full universe of 100,000+ stocks across 73 exchanges using stocks trading below book value alongside the rest of the 120-indicator composite, with sector percentiles and historical trends shown on every stock profile.
Related ValueMarkers Resources
- Piotroski F-Score — Piotroski F-Score captures the reliability of reported earnings versus underlying cash flow
- Graham Number — Graham Number captures how cheaply a stock trades relative to its fundamentals
- DCF Intrinsic Value — DCF captures how cheaply a stock trades relative to its fundamentals
- What Time Does Stock Market Close Today — related ValueMarkers analysis
- Portfolio Rebalancing How And When To Rebalance Your Portfolio — related ValueMarkers analysis
- Michael Burry Letter — related ValueMarkers analysis
Frequently Asked Questions
what stocks to buy
The stocks worth buying right now are those where a systematic four-filter analysis (DCF gap above 20%, Piotroski F-Score of 7+, ROIC above 10%, and debt-to-equity below 1.5) produces a positive result on a business you understand. JNJ at P/E 15.2 and 3.1% yield fits the profile for quality-oriented investors. Industrials at cyclical trough earnings fit for investors comfortable with near-term volatility in exchange for normalized earnings upside.
what are penny stocks
Penny stocks are shares priced below $5, typically on low-volume markets or over-the-counter systems. Value investing frameworks systematically exclude penny stocks because their accounting quality signals are unreliable, trading liquidity is insufficient for meaningful position sizing, and the Piotroski F-Score cannot be applied consistently to companies with missing or non-GAAP financials. They occupy a different risk category than undervalued mid and large-cap equities.
what are the best stocks to buy right now
The best stocks to buy right now are those clearing all four quantitative filters (valuation, quality, integrity, and margin of safety) on businesses with durable competitive positions and identifiable catalysts to close the discount. As of Q3 2026, healthcare names with P/E below their 10-year averages, select industrials at earnings trough, and non-US financials earning above cost of equity at P/B below 1.0 represent the most consistent opportunities. Run the ValueMarkers screener filtered by VMCI Value above 7 for a current ranked list.
what is eps in stocks
EPS is earnings per share: the company's net income divided by diluted shares outstanding. It measures profitability per unit of ownership. For undervalued stock analysis, the trailing EPS feeds the P/E ratio and the Graham Number calculation. The five-year EPS growth rate determines how much of the undervaluation gap will be filled by earnings growth versus multiple expansion. JNJ at $9.80 EPS growing at 5% per year compounds to roughly $12.50 in five years, which at a 16x multiple would price the stock near $200.
what is beta in stocks
Beta measures correlation and magnitude of price movement relative to the index. A stock with beta 0.55 like KO will fall roughly half as much as the market in a broad selloff, and rise roughly half as much in a rally. For value investors, low-beta undervalued stocks reduce the emotional difficulty of holding through volatility. High-beta undervalued stocks maximize the return when the thesis is right but require stronger conviction to hold through inevitable corrections. Position size should scale inversely with beta when the analysis is less certain.
when will now stock split
NOW (ServiceNow) has not announced a stock split as of Q3 2026. The company's share price has moved above $1,000 historically but ServiceNow management has not pursued splits as a capital strategy. Splits have no impact on intrinsic value; they only change the number of shares and price per share arithmetically. Value investors treat split announcements as noise unless they are accompanied by a material change in earnings guidance or capital allocation policy.
Run the ValueMarkers screener to apply Piotroski F-Score, Graham Number, and DCF filters simultaneously across 73 global exchanges and find the undervalued stocks right now that match your own criteria.
Written by Javier Sanz, Founder of ValueMarkers. Last updated April 2026.
Ready to find your next value investment?
ValueMarkers tracks 120+ fundamental indicators across 100,000+ stocks on 73 global exchanges. Run the methodology above in seconds with our stock screener, or see today's top-ranked names on the leaderboard.
Related tools: DCF Calculator · Methodology · Compare ValueMarkers
Disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.